RHHBF Financials: Roche Holding AG AI Analysis



Financials

RHHBF Financial

Roche Holding AG

0%

$0

As of today:May 12, 11:38:48 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Roche Holding Ltd?

Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Features

Markets

News

Breakdown	TTM	12/31/2025	06/30/2025	12/31/2024	06/30/2024	12/31/2023
Revenue	61,516	30,572	30,944	30,647	29,848	28,937
Revenue Growth (YoY)	2%	0%	4%	6%	0%	-7%
Cost of Revenue	16,230	8,481	7,749	8,311	7,472	7,982
Gross Profit	45,286	22,091	23,195	22,336	22,376	20,955
Selling, General & Admin	13,838	7,330	6,508	7,382	6,376	7,013
Research & Development	12,243	6,169	6,074	6,774	6,268	6,788
Operating Expenses	24,118	12,585	11,533	13,187	11,438	12,979
Other Non Operating Income (Expenses)	-159	-78	-81	-84	-88	-99
Pretax Income	16,973	7,385	9,588	3,570	8,223	4,905
Income Tax Expense	3,174	1,418	1,756	1,080	1,526	110
Net Income	12,880	5,470	7,410	2,019	6,258	4,361
Net Income Growth	56%	171%	18%	-54%	-12%	12%
Shares Outstanding (Diluted)	803	803	803	802	802	804
Shares Change (YoY)	0%	0%	0%	0%	0%	0%
EPS (Diluted)	16.03	6.81	9.22	2.52	7.8	5.42
EPS Growth	55%	170%	18%	-54%	-12%	12%
Free Cash Flow	10,906	6,967	3,939	9,263	5,822	5,522
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	73.61%	72.25%	74.95%	72.88%	74.96%	72.41%
Operating Margin	34.41%	31.09%	37.68%	29.85%	36.64%	27.56%
Profit Margin	20.93%	17.89%	23.94%	6.58%	20.96%	15.07%
Free Cash Flow Margin	17.72%	22.78%	12.72%	30.22%	19.5%	19.08%
EBITDA	21,471	9,648	11,823	9,317	11,121	8,142
EBITDA Margin	34.9%	31.55%	38.2%	30.4%	37.25%	28.13%
D&A For EBITDA	303	142	161	168	183	166
EBIT	21,168	9,506	11,662	9,149	10,938	7,976
EBIT Margin	34.41%	31.09%	37.68%	29.85%	36.64%	27.56%
Effective Tax Rate	18.7%	19.2%	18.31%	30.25%	18.55%	2.24%

Breakdown

TTM

12/31/2025

06/30/2025

12/31/2024

06/30/2024

12/31/2023

Revenue

61,516

30,572

30,944

30,647

29,848

28,937

Revenue Growth (YoY)

-7%

Cost of Revenue

16,230

8,481

7,749

8,311

7,472

7,982

Gross Profit

45,286

22,091

23,195

22,336

22,376

20,955

Selling, General & Admin

13,838

7,330

6,508

7,382

6,376

7,013

Research & Development

12,243

6,169

6,074

6,774

6,268

6,788

Operating Expenses

24,118

12,585

11,533

13,187

11,438

12,979

Other Non Operating Income (Expenses)

-159

-78

-81

-84

-88

-99

Pretax Income

16,973

7,385

9,588

3,570

8,223

4,905

Income Tax Expense

3,174

1,418

1,756

1,080

1,526

110

Net Income

12,880

5,470

7,410

2,019

6,258

4,361

Net Income Growth

56%

171%

18%

-54%

-12%

12%

Shares Outstanding (Diluted)

803

802

804

Shares Change (YoY)

EPS (Diluted)

16.03

6.81

9.22

2.52

7.8

5.42

EPS Growth

55%

170%

18%

-54%

-12%

12%

Free Cash Flow

10,906

6,967

3,939

9,263

5,822

5,522

Free Cash Flow Per Share

Gross Margin

73.61%

72.25%

74.95%

72.88%

74.96%

72.41%

Operating Margin

34.41%

31.09%

37.68%

29.85%

36.64%

27.56%

Profit Margin

20.93%

17.89%

23.94%

6.58%

20.96%

15.07%

Free Cash Flow Margin

17.72%

22.78%

12.72%

30.22%

19.5%

19.08%

EBITDA

21,471

9,648

11,823

9,317

11,121

8,142

EBITDA Margin

34.9%

31.55%

38.2%

30.4%

37.25%

28.13%

D&A For EBITDA

303

142

161

168

183

166

EBIT

21,168

9,506

11,662

9,149

10,938

7,976

EBIT Margin

34.41%

31.09%

37.68%

29.85%

36.64%

27.56%

Effective Tax Rate

18.7%

19.2%

18.31%

30.25%

18.55%

2.24%

Follow-Up Questions

What are Roche Holding AG's key financial statements?



According to the latest financial statement (Form-10K), Roche Holding AG has a total asset of $0, Net loss of $0

What are the key financial ratios for RHHBF?



Roche Holding AG's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Roche Holding AG's revenue broken down by segment or geography?



Roche Holding AG largest revenue segment is Roche Pharmaceuticals, at a revenue of 43,297,000,000 in the most earnings release.For geography, Switzerland is the primary market for Roche Holding AG, at a revenue of 747,000,000.

Is Roche Holding AG profitable?



no, according to the latest financial statements, Roche Holding AG has a net loss of $0

Does Roche Holding AG have any liabilities?



no, Roche Holding AG has liability of 0

How many outstanding shares for Roche Holding AG?



Roche Holding AG has a total outstanding shares of 0

Roche Holding AG (RHHBF) Financial

RHHBF Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Roche Holding Ltd?

Roche Holding AG (RHHBF) Financial

RHHBF Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Roche Holding Ltd?

RHHBF Income

Follow-Up Questions

What are Roche Holding AG's key financial statements?

What are the key financial ratios for RHHBF?

How is Roche Holding AG's revenue broken down by segment or geography?

Is Roche Holding AG profitable?

Does Roche Holding AG have any liabilities?

How many outstanding shares for Roche Holding AG?